Quest Diagnostics Projects FY Adjusted EPS Between $10.63 and $10.83
DGX sits 24% above its 52-week low of $160.02 on elevated volume (2.0× avg).
Summary
Quest Diagnostics has provided its full-year adjusted EPS guidance, projecting a range of $10.63 to $10.83. This new guidance sets the financial outlook for the current fiscal year, following the company's strong Q4 and FY25 results reported in February, which included a dividend increase and a share repurchase authorization. While the headline does not indicate how this guidance compares to analyst consensus or previous company forecasts, it provides a critical benchmark for investors and analysts to update their financial models. Traders will be evaluating this range against market expectations to assess potential implications for the stock.
At the time of this announcement, DGX was trading at $198.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $21.6B. The 52-week trading range was $160.02 to $213.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.